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     Objectives:  There have been many studies suggesting that localized 
scleroderma has an strong autoimmune background, although the lesions are usually 
limited to the skin and subcutaneous tissue.  In this review paper we summarize the 
previous data on the autoimmunity of localized slceroderma mostly published in this 
two decades, because there has not been a review paper summarizing autoimmunity in 
this disorder. 
     Methods:  We classified the previous reports into three categories;  antinuclear 
antibodies, cytokine and soluble receptors, and cell adhesion molecules and cell surface 
molecules.  In each category, we introduce the important investigations. 
     Results:  High frequencies of antinuclear antibodies by the indirect 
immunofluorescence method using cultured cells are confirmed by many groups.  
Afterwards, the major autoantigen were revealed to be histones.  Recently, 
anti-topoisomerase II alpha antibody was found to be highly frequently detected in 
localized scleroderma, while anti-topoisomerase I antibody which is highly specific for 
systemic sclerosis, was not detected in any case of localized scleroderma.  Other 
studies related that the elevated serum cytokines and cell adhesion modecules suggested 
the immunoactivation of localized scleroderma. 
     Conclusions:  Many previous studies conclude that localized scleroderma 
involves autoimmune abnormalities and is one of the organ-specific autoimmune 
disorders targeting mainly skin, although the type of autoimmune abnormalities are 
different from systemic sclerosis. 
 
Introduction
     Scleroderma is a chronic disease of unkown etiology charectarized by skin 
fibrosis and is devided into two clinical entities:  localized scleroderma and systemic 
sclerosis (SSc).  Localized scleroderma differs from SSc in that it is not accompanied 
by Raynaud's phenomenon, acrosclerosis and internal organ involvement and the life 
prognosis of patients with localized scleroderma is good. 
       In localized scleroderma, the lesions are usually limited to the skin and 
subcutaneous tissue as fatty tissue, muscle and sometimes bone beneath the cutaneous 
lesions, lacking Raynaud’s pheromenon, arthritis or other systemic symptoms. 
Tuffanelli and Winkelmann classified localized scleroderma into the following three 
types (1), and this classification has been widely accepted. 
       Morphea is usually characterized by circumscribed, sclerotic plaques with an 
ivory-colored center and surrounding violaceous halo.  Morphea punctate is considered 
to be a variant of morphea, where there appear small plaque complexes. 
       Linear scleroderma appears in a linear bandlike distribution and scleroderma en 
bondes is a synonimu of linear scleroderma.  The frontal of frontoarietal linear 
sclerderma ( en coup de sabre ) is characterized by atrophy and a furrow or depression 
that extends below the level of the surrounding skin. 
      Generalized morphea, the most severe form of localized scleroderma, is 
 2
characterized by widespread skin involvement with multiple indurated plaques, 
hyperpigmentation and frequent muscle atrophy.  Although the diagnostic criteria for 
generalized morphea differ among investigators, we defined patients as having 
generalized morphea when they fulfilled the following two criteria:  (1) four or more 
lesions more than 3 cm in diameter, irrespective of whether they were of the morphea or 
linear type;  and (2) involvement of two or more areas of the body of seven areas, the  
seven areas being head and neck, right upper extremity, left upper extremity, anterior 
trunk , posterior trunk, right lower extremity and left lower extremity (3).  Patients 
who did not meet these criteria were diagnosed as having morphea or linear scleroderma 
according to the morphologic features.  All of our studies were conducted using this 
classification. 
        Autoimmune abnormalities of localized scleroderma have been well 
recognized in the last two decades and recently this disease is generally considered to 
have an autoimmune background.  The first description of this concept was proposed 
by our study in 1983, which reported high frequency of antinuclear antibodies (72.7%, 
16/22), using cultured human cells as the substrate for detection by the indirect 
immunofluorescence method (2). 
         At present, the specificity of antinuclear antibodies in localized scleroderma 
has been revealed as decribed in the following sections (Table 1).  In addition, an 
immune activation was shown in localized scleroderma suggested by the elevation of 
some cytokines (Table 2), soluble cell adhesion molecules and soluble cell surface 
antigens (Table 3). 
        In this literature, we summarized the previous studies related to an 
autoimmune background and immune activation, the latter which is comparable with 
diffuse form of SSc.  Many previous studies conclude that localized scleroderma 
involves autoimmune abnormalities, though they are different from SSc. 
Antinuclear Antibody
      It was demonstrated that in an indirect immunofluorescence test for antinuclear 
antibody, the sensitivity varied with the type of substrate used and cultured human cell 
substrates had been shown to increase sensitivity compared with animal tissue sections. 
Therefore, cultured human cells such as HEp-2 cells are widely used for the screening 
test for antinuclear antibody at the clinical level nowadays. 
      The first investigation on the frequency of antinuclear antibody in localized 
scleroderma using cultured human cell substrates was reported by us in 1983 and 
demonstrated greater sensitivity (72.7%)(2) than animal tissue sections of previous 
reports (4-7).   The high frequency of antinuclear antibody in localized scleroderma by 
an indirect immunofluorescence method using cultured cells was confirmed by other 
groups (8-11).  Immunofluorescence staining patterns including homogeneous, 
speckled or nucleolar stainings were not uniform in localized scleroderma, suggesting 
the heterogeneity of antinuclear antibody in localized scleroderma, although a major 
immunofluoresence pattern was homogeneous with chromosomal staining and the 
major nuclear antigens of this homogeneous pattern with chromosomal staining were 
not identified at this time, because anti-double-stranded DNA (dsDNA) or 
anti-topoisomerase I antibody were not detected (2). 
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     We have an impression that the patients with early onset have more elevated titers 
of antinuclear antibodies and hope to reveal that after accumulation of more cases. 
 
Anti-single-stranded DNA (ssDNA) antibody  
        The first report on the presence of anti-single-stranded DNA antibody was by 
Rodnan et al. in 1977 (4), although this was an abstract and the details were not 
described.  Seven years after this report, Falanga et al. described the high titer of 
anti-single-stranded DNA antibody in linear scleroderma; all seven patients were 
initially found to have antibodies to double-stranded DNA using the Farr technique, 
however, their detailed investigation using Crithidia luciliae assay and single-stranded 
DNA labeled with iodine 131 disclosed high titers of antibodies to single-stranded DNA 
and absent double-stranded DNA antibodies (12).  Moreover, anti-single-stranded 
DNA  antibody was considerably higher than the mean for unselected patients with 
systemic lupus erythematosus (SLE). The next year, they showed a positive correlation 
between anti-single-stranded DNA antibody and joint contracture or active disease with 
a duration of longer than 2 years (8). 
      We have also confirmed elevated levels of anti-single-stranded antibody in both 
IgG and IgM levels by ELISA analysis in localized scleroderma (13).  Moreover, we 
found that the patients with linear scleroderma accompanied by muscle involvement 
such as muscle sclerosis, muscle atrophy or muscle convulsion had significantly 
elevated levels of  anti-single-stranded DNA antibody as compared with patients 
without muscle involvement (14).  The titer of anti-single-stranded DNA antibody is 
well correlated with disease activity and responds to oral corticosteroid treatment in the 
patients with severe muscle involvement and have shown two typical cases in the Figure 
1 (unpublished data). 
     Subsequently, Falanga et al. reported the high frequency (59%) of 
anti-single-stranded DNA antibody in morphea and generalized morphea, with the 
highest levels of single-stranded DNA binding observed in patients with generalized 
morphea (14).  The frequency of antibodies to single-stranded DNA was higher in 
patients with clinical evidence of active lesions compared with inactive disease. 
      Ruffatti et al. also confirmed the high frequency (38.5%) of anti-single-stranded 
DNA antibody by ELISA in 52 patients with localized scleroderma and found that the 
anti-single-stranded DNA antibodies in localized scleroderma were mainly 
characterized by high levels of IgM and IgA isotypes (15).  In contrast, the IgG isotype 
of anti-single-stranded DNA antibodies significantly prevailed in SLE. 
     Thus, the clinical significance of anti-single-stranded DNA antibody in localized 
scleroderma was widely accepted, although the major nuclear antigen had still not been 
identified at this time, because anti-single-stranded DNA antibody does not produce any 




      One decade after the first report on the high frequency of antinuclear antibody in 
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localized scleroderma (2), we found evidence suggesting the presence of antihistone 
antibodies in a preliminary study by the new technique of immunoblotting analysis 
using crude nuclear antigens.  Afterwards, we confirmed the presence of antihistone 
antibody by ELISA and by immunoblotting analysis using purified histone antigens 
(16). 
        By ELISA, antihistone antibodies were demonstrated in 47% (23/49) of 
patients with localized scleroderma and in 87% (13/15) of patients with generalized 
morphea.  Immunoblotting analysis revealed that predominant antigens were histones 
H1 and H3.  The reactivity against H2A and H2B was also observed.  The presence 
of antihistone antibodies correlated with that of anti-single-stranded DNA antibody. 
     Further studies revealed the clinical characteristics associated with antihistone 
antibodies in patients with localized scleroderma (3).  The presence of antihistone 
antibodies strongly correlated with the number of morphea lesions, total number of 
lesions and number of involved ares of the body, however, they did not correlate with 
the presence or number of linear lesions.  If we followed the classification definition of 
generalized morphea described in the introduction section, antihistone antibodies would 
be a good serologic marker for generalized morphea with 87% sensitivity and  74% 
specificity. 
      In addition, we determined the reactivity of antihistone antibodies with five 
individual histones (H1,H2A,H2B, H3 and H4) as native forms in each subgroup of 
localized scleroderma by ELISA.  In all three groups, IgG antihistone antibodies 
strongly reacted with H1, H2A and H2B,  and IgM antihistone antibodies strongly 
reacted with H1 and H2B (17).  An homogeneous immunofluorescence pattern with 
chromosomal staining on HEp-2 cells was completely abolished by absorption with 
total histones, suggesting that antihistone antibodies produced homogeneous stainings 
by the indirect immunofluorescence technique. These data suggest that antihistone 
antibodies in localized scleroderma are directed against native chromatin, since H1, 
H2A and H2B occupy a relatively exposed component of native chromatin. 
      Antihistone antibodies were originally considered a highly specific serological 
marker of drug-induced lupus erythematous, although our studies led to the idea that 
antihistone antibodies are commonly detected in both SSc (18) and localized sclerderma 
(3, 16, 17):  this concept was confirmed by other groups (10, 19). 
Rheumatoid factor
       Rheumatoid factor is generally considered to be a serological marker for 
rheumatoid arthritis, although the low titer of these autoantibodies was widely defected 
in various autoimmune disorders.  In localized scleroderma, we investigated 
rheumatoid factor to assess the cross-reactivity of antihistone antibodies.  By 
employing a latex agglutination test, IgM rheumatoid factor was detected in 60% of 20 
patients with localized scleroderma and at a frequency of 82% in those with generalized 
morphea (17).  In addition, an absorption test of rheumatoid factor activity with human 
IgG revealed no cross-reactivity of antihistone antibodies with rheumatoid factor. The 
high frequency of rheumatoid factor was confirmed by other investigators (9). 
Anti-topoisomerase II antibody
     Anti-topoisomerase I antibody is highly specific for diffuse cutaneous SSc (20) 
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and is not defected in localized scleroderma (2, 8).  However, our recent study revealed 
that patients with localized scleroderma were frequently positive for anti-topoisomerase 
II α antibody (76%, 35/46), although this antibody is not completely specific for 
localized scleroderma;  14% (5/37) in systemic sclerosis, 8% (2/26) in SLE and 10% 
(2/20) in dermatomyositis (21).  Immunoblotting analysis confirmed the 
no-cross-reactivity of anti-topoisomerase IIα antibody with topoisomerase I.  In 
addition, anti-topoisomerase IIα  antibody was shown to have the capability of 
inhibiting topoisomerase IIα enzymatic activity. 
      Topoisomerases, which are ubiquitous enzymes, can modulate the topologic 
state of DNA that is critical for important biological processes such as DNA replication, 
nucleosome assembly and transcription.  Topoisomerase I breaks and rejoins only 1 of 
the 2 strands for each DNA strand-passing reaction, while topoisomerase II breaks and 
rejoins both strands.  Thus, topoisomerase family are targeting antigents both in SSc 
and localized scleroderma, although disease specificity is quite different.  As described 
before, anti-topoisomerase I antibody is almost exclusively detected in SSc, whereas 
antitopoisomerase IIα antibody was first reported in idiopathic pulmonary fibrosis 
(22) and various autoimmune conditions.  Among them, frequency (76%) in localized 
scleroderma, especially that (85%, 11/13) in generalized morphea, is predominantly 
high. 
Antiphospholipid antibody
      Antiphospholipid antibodies are detected in a variety of autoimmune disorders, 
including SLE,  infectious diseases, and in patients receiving drugs such as 
procainamide and chlopromazine,  Patients with these antibodies are considered to 
have a higher risk of vascular thrombosis.  Localized scleroderma and drug-induced 
lupus share many immunological characteristics.  Antihistone antibodies and 
anti-single stranded DNA antibodies are commonly observed in both diseases, but 
anti-double stranded DNA antibodies were absent.  Therefore we investigated whether 
antiphospholipid antibodies were detected in patients with localized scleroderma (23).  
Exceeding our expectations, IgM and/or IgG anticardiolipin antibodies were positive in 
46% of patients with localized scleroderma, with 67% in generalized morphea, 35% in 
linear scleroderma and 30% in morphea.  In generalized morphea, the frequency of 
IgM anticardiolipin antibody (61%) was much higher than that of IgG antibody (28%).  
In contrast, anti-β2 glycoprotein I antibody was not detected in any case. 
     In the same study, lupus anticoaglant by screening and confirmatory coagulation 
tests was detected in 24% (5/21) sera from patients with localized scleroderma;  all 
five patients had generalized morpea.  Careful clinical investigation for thrombosis 
revealed one case with pulmonary embolism.  We feel more careful observation and 
follow up for thrombosis should be required for patients with generalized morphea with 
antiphospholipid antibodies. 
Antinuclear antibodies commonly defected in SSc
     Localized scleroderma and SSc share the same main clinical features of skin 
sclerosis, however clinical features of both diseases are quite different and they 
generally considered to be two different clinical entities.  In both two diseases, 
autoantibodies are commonly detected and immunological abnormalities involve the 
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pathogenesis of both diseases. 
     The most representative autoantibodies very frequently detected in diffuse 
cutaneous SSc are anti-topoisomerase I antibody and anti-RNA polymerase antibody.  
Anti-topoisomerase I antibody has not been detected in any study of localized 
scleroderma as described before (2, 8), and anti-RNA polymerase antibody has not been 
detected in any case of localized scleroderma either ( unpublished data). 
     In contrast, several autoantibodies are well known to be found in limited 
cutaneous SSc, and the most representative autoantibody of limited cutaneous SSc is 
anticentomere antibody.  In localized scleroderma, only one study reported 3 cases 
with anticentromere antibody and without evidence of Raynaud's phenomenon, 
acrosclerosis or visceral involvement during the follow-up period (8).  However, none 
of other studies which screened for the presence of anticentromere antibody failed to 
detect this antibody (2, 3, 7, 10, 19, 20), and the cases with localized scleroderma 
having anticentromere antibody seem to be exceptionally rare cases in this clinical 
entity. 
     Anti-U3 RNA antibody was reported to be detected in 3 cases of 70 patients with 
localized scleroderma using RNA immunoprecipitation analysis (24).  The presence of 
antibodies to Th/To RNP was also reported by the same group and being detected in 4% 
(3/70) patients with localized scleroderma by the same method (25).  These two 
autoantibodies were originally identified in patients with SSc having antinucleolar 
antibody and were considered to be a serological marker antibody for SSc.  However, 
these observations may explain the fact that a small number of sera from patients with 
localized scleroderma produced nucleolar staining by the indirect immunofluorescence 
method.  The clinical significance of the presence of these antibodies has not been 
clarified at present. 
Other autoantibodies
     The previous studies show that stress proteins such as histone H2B, heart shock 
protein 73 (hsp-73), hsp-90 and ubiquitin may have an important role in the 
pathogenesis of various autoimmune diseases.  As described before, histone H2B is an 
autoantigen in localized scleroderma, SLE and other disorders (17, 26), and histone 
H2B was defined as a member of the stress protein family (27).  Thus, we next 
investigated the presence of autoantibody against hsp-73 in localized scleroderma and 
detected 33% (19/57).  This frequency was compareble with 30% (9/30) in SLE and 
41% (13/32) in SSc (28). 
     In addition, recent studies revealed that localized scleroderma shares the same 
autoantibodies with other autoimmune conditions.  Anti-Fcγreceptor autoantibodies 
originally found in autoimmune mice (29) were detected in 54% of patients with 
localized scleroderma (30), the same with SSc, SLE and Sjögren syndrome (31, 32).  
Autoantibodies to mitochondria generally considered to be detected in primary biliary 
cirrhosis (PBC), were detected in 6 of 60 patients with localized scleroderma (33).  
These patients may comprise a unique subset of localized scleroderma designated 
multiple plaque type of generalized morphea with later onset, although only one patient 
showed laboratory abnormalities suggestive of PBC.  Next, Arnett et al. reported that 
autoantibodies to fibrillin 1 were detected in 28% (14/50) patients with localized 
 7
scleroderma (34).  Fibrillin 1 is the major component of microfibrils and Fibrillin 1 
gene abnormalies are shown to be related to the animal model of scleroderma, the 
tight-skin mouse 1 ( TSK1) (35) and the native American population with a high 
incidence of diffuse SSc (36).  Autoantibody to fibrillin 1 is also detected in 94% of 
native American patients and 87% of Japanese patients with diffuse SSc and less 
commonly in Caucasian (34%) and Aflican American (7%) SSc patients (37). 
Cytokines and their soluble receptors
     The autoantibody production in localized scleroderma described above can be 
partially attributed to abnormal T cell and/or B cell activation. Some major lymphocyte 
activations are mediated through circulating cytokines such as interleukin (IL)-2, IL-4 
and IL-6.  In our previous study, serum IL-2 levels in 27% (13/48) of patients with 
localized scleroderma, serum IL-4 levels in 17% (8/48) and serum IL-6levels in 47% 
(23/48) were elevated, while none of the healthy controls had elevated levels of 
cytokines of these types (38). Moreover, activated lymphocytes express cytokine  
receptors on their surfaces and a soluble part of these receptors is released in proportion 
to state activation.  We have investigated these receptors.  Soluble IL-2 receptor 
( sIL-2R) levels have been shown to be elevated in various autoimmune disorders such 
as SLE and SSc (39, 40).  Like the above systemic autoimune disorders, serum levels 
of sIL-2R were shown to be frequently elevated (21%, 10/48), and they correlated with 
the number of sclerotic lesions and the number of involved areas (41).  Two surface 
transmembrane protein receptors of IL-6 (sIL-6R) , a ligand binding submit of 80 kDa 
and a transducting 130 kDa glycoprotein (gp130), were known to be related to signal 
pathways.  The soluble form ot IL-6 receptor is capable of activation of the IL-6 
pathway, although soluble forms of gp130 inhibit IL-6 activities through binding IL-6 
receptors by activating signaling pathways.  In localized scleroderma, elevated sIL-6R 
levels significantly correlated with the number of linear lesions and the number of body 
areas involved (42).  Elevated sgp130 levels were also associated with the number of 
total lesions and the number of body areas involved. 
Soluble cell adhesion molecules
    Cell adhesion molecules are important in a variety of inflammatory and 
immuno-mediated mechanisms, including lymphocyte recruitment and targeting.  
Intracellular adhesion molecule-1 (ICAM-1:  CD54), vascular cell adhesion 
molecule-1 (VCAM-1, CD106) and E-selection (CD62P) were expressed by activated 
endothelial cells. Souble forms of these molecules are serological indicators of immune 
activation.  In localized scleroderma, the targeting organ is limited to the 
circumscribed skin, although elavated levels of soluble ICAM-1 (25%, 12/48), elevated 
soluble VCAM-1 (19%, 11/59) and elevated soluble E-selectin (20%, 12/59) were 
detected (41,42). 
Soluble cell surface antigens of lymphocytes
     Several soluble cell surface antigens of lymphocytes are known as serological 
indicators of immune activation, as soluble CD23 (sCD23) is an indicator of B cell 
activation, soluble CD4 and CD8 (sCD4 and sCD8) of for T cell activation, and soluble 
CD30 (sCD30) of Th2-type lymphocyte.  All these molecules have been shown to be 
elevated in various autoimmune disorders and we have investigated these molecules in 
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localized scleroderma, where  elevated frequencies of sCD23 (20%, 10/49), sCD4 
(18%, 9/49), sCD8 (20%, 10/49) and sCD30 (33%, 18/55) were confirmed (43, 44, 45). 
Conclusion
    As described above, the presence of autoantibodies and the elevated serological 
markers suggesting immune activation show that localized scleroderma is one of the 
organ-specific autoimmune disorders targeting skin.  Among three subsets of localized 
scleroderma, generalized morphea is considered to have a stronger autoimmune 
background than the other two types. 
     Whether the presence of various autoantibodies are related to the pathogenesis of 
cutaneous lesions remains to be determined.  In addition, complicated cytokine 
cascades seem to be involved in the development of this disorder. Soma et al. reported 
the cases of lacalized scleroderma having multiple lesions, although they belong to 
Blaschko’s lines (46).  We hypothesize that mutant cells derived from one cell orgin 
distributed in the lesions belong to Blaschko’s line may be a target for the autoimmune 
reaction of localized scleroderma.  More investigation to reveal the detailed process of 
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Figure1. Clinical courses,treatment and titers of anti-SS-DNA antibodies.
case1. Fifteen year old female was seen with a complain of disturbed movement of 
left lower leg.She was successfully treated with 1㎎ of betamethasone per day.
case2.Nine year old male was seen with a complain of rapid increasing of multiple 
sclerotic plaques.He was successfully treated with 10㎎ of prednisolone per day.











Highly specific antinuclear 
antibody (ANA)   
 
 
Homogeneous ANA by indirect 
immunofluorescence using HeLa cells 2) 73%      - 0% 
Anti-single-standed antibody 12) 50% - - 
Anti-histone antibody 16) 47% 20% 0% 
Anti-topoisomerase IIα antibody 22) 76% 14% 7% 
ANA commonly detected in SSc     
Anticentromere antibody 8) 12% 42% 0% 
Anti-U3 RNP antibody 24) 4% - - 
Anti-Th/To RNP antibody 25) 4% - - 
Other autoantibodies     
Rheumatoid factor 17) 60% - - 
Antiphospholipid antibody 23) 46% 0% 5% 
Anti-hsp-73 antibody 27) 33% 41% 0% 
Anti-mitochondria antibody 33) 10% - 0% 
Anti-Fc-γ receptor antibody 30) 54% 66% 0% 
Anti-Fibrillin 1 antibody 34) 28% - 6% 
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table 3  Abnormalities of soluble forms of cell adhesion molecules 



































































GM: Generalized morphea 
LS: Linear Scleroderma 
M: Morphea 
